SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

December 28, 2010 14:46 ET

Investor Relations Digital Campaigning and Media Solutions Provider Investor Candy Reports Radient Pharmaceuticals' Campaign Activities Generating Results

TUSTIN, CA--(Marketwire - December 28, 2010) - Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic (IVD) cancer tests, including its FDA-approved Onko-Sure® IVD cancer test, announced today its investor relations partner released RPC's campaign results. 

RPC engaged Investor Candy in the Fall of FY2010 to assist with broad-based investor outreach efforts investors. Through the launch of a new and innovative investor-focused website and digital campaign supported by Investor Candy, along with the Company's on-going investor relations programs, RPC has elevated company and product awareness to existing and prospective shareholders, the broad investment community at large and to healthcare professionals and their patients. More importantly, this is evidenced in a gain in stock price over from approximately a $.40 per share price six months ago to a $1.10 share price and 15 million trading volume as of December 23, 2010.

"This is the kind of result we strive for," commented Curtis Hollister, CEO of Investor Candy. "We are extremely selective in choosing companies we believe have the management, operations and product and that can grow an organization for the long term. When investors have access to strong management in solid companies, there is often a positive impact on the trading price and volume of the company. In most circumstances institutional investors are the only audience to have the privilege of hearing directly from management. Investor Candy is focused on democratizing this process by giving clients an innovative and direct way to scale these previously expensive and time consuming conversations to a much larger and broader audience."

"With RPC's Investor Channel and Digital Campaigning we have expanded our reach into new audiences and enhanced communication with current RPC investors," said Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals. "For a small cap company like ours communicating our value proposition to existing and prospective investors and other audiences is a major challenge. This approach is making a positive difference which is currently reflecting in our share price."

RPC's investor videos are accessible and viewable through personal computers and handsets with a 3G connection by visiting http://ec2‐174‐129‐47‐89.compute‐1.amazonaws.com/. For additional information on Radient Pharmaceuticals and its portfolio of IVD cancer products visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information, contact Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products, visit the Company's corporate website at www.radient-pharma.com. For Investor Relations information, contact Kristine Szarkowitz at IR@RadientPharma.com or 1.206.310.5323.

About Investor Candy:
Based in Ottawa, Canada, Investor Candy (www.investorcandy.com) delivers digital campaigning and investor media solutions to help good companies become market leaders. The initial technology offering from the company is the Investor Channel, an advanced Investor Relations platform that facilitates digital campaigning and allows public issuers to increase the effectiveness and scale of their investor communications, visit www.investorcandy.com.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • RPC Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    (Tel : ) 206.310.5323